Actemra is a humanised monoclonal antibody to the IL-6 receptor, inhibiting the activity of IL-6, a protein that plays a key role in the rheumatoid arthritis inflammation process.
-
Roche Pharmaceuticals' R&D facility in Basel Switzerland. -
Biopharmaceutical production at Roche. Actemra was first deployed in Japan... -
Roche's MabThera / Rituxan has recently been approved for the additional... -
Actemra is a humanised monoclonal antibody to the IL-6 receptor, inhibiting... -
Roche's MabThera / Rituxan is an anti-CD20 monoclonal antibody.
